Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 2
2005 1
2006 2
2007 2
2008 2
2009 2
2010 2
2011 7
2012 3
2013 3
2014 4
2015 2
2016 4
2017 3
2019 2
2020 2
2021 3
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets.
Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L. Zádori D, et al. J Alzheimers Dis. 2014;42 Suppl 3:S177-87. doi: 10.3233/JAD-132621. J Alzheimers Dis. 2014. PMID: 24670398 Review.
The impairment of glutamatergic neurotransmission plays an important role in the development of Alzheimer's disease (AD). The pathological process, which involves the production of amyloid-beta peptides and hyperphosphorylated tau proteins, spreads over well- …
The impairment of glutamatergic neurotransmission plays an important role in the development of Alzheimer's disease (AD …
Reduced biophotonic activities and spectral blueshift in Alzheimer's disease and vascular dementia models with cognitive impairment.
Wang Z, Xu Z, Luo Y, Peng S, Song H, Li T, Zheng J, Liu N, Wu S, Zhang J, Zhang L, Hu Y, Liu Y, Lu D, Dai J, Zhang J. Wang Z, et al. Front Aging Neurosci. 2023 Sep 1;15:1208274. doi: 10.3389/fnagi.2023.1208274. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37727319 Free PMC article.
BACKGROUND: Although clinically, Alzheimer's disease (AD) and vascular dementia (VaD) are the two major types of dementia, it is unclear whether the biophotonic activities associated with cognitive impairments in these diseases share common pathological featu …
BACKGROUND: Although clinically, Alzheimer's disease (AD) and vascular dementia (VaD) are the two major types of dement …
Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on streptozotocin-induced Alzheimer's disease models.
Liu P, Wang C, Chen W, Kang Y, Liu W, Qiu Z, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T. Liu P, et al. Phytomedicine. 2023 Jan;109:154594. doi: 10.1016/j.phymed.2022.154594. Epub 2022 Dec 10. Phytomedicine. 2023. PMID: 36610115
BACKGROUND: Over-activation of N-methyl-D-aspartate receptors (NMDARs) is involved in sporadic Alzheimer's disease. Silibinin, a natural flavonoid gained from the seeds of Silybum marianum, exerts neuroprotective effects on sporadic AD models, but its impacts …
BACKGROUND: Over-activation of N-methyl-D-aspartate receptors (NMDARs) is involved in sporadic Alzheimer's disease. Sil …
2-{[4-(4-[125I]Iodobenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol.
Chopra A. Chopra A. 2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21473031 Free Books & Documents. Review.
These receptors are involved in the development of neurological conditions such as Parkinson's disease, Alzheimer's disease, bipolar disorder, etc (2, 3). The structure, distribution, and function of the NMDAR in the rodent brain has been reviewed else …
These receptors are involved in the development of neurological conditions such as Parkinson's disease, Alzheimer's …
Targeting NMDA receptor in Alzheimer's disease: identifying novel inhibitors using computational approaches.
Siddiqui AJ, Badraoui R, Jahan S, Alshahrani MM, Siddiqui MA, Khan A, Adnan M. Siddiqui AJ, et al. Front Pharmacol. 2023 Jun 21;14:1208968. doi: 10.3389/fphar.2023.1208968. eCollection 2023. Front Pharmacol. 2023. PMID: 37416066 Free PMC article.
Allosteric inhibitors of GluN2B-containing receptors are among the most potential NMDAR targeting drugs. Since the discovery of ifenprodil, a variety of GluN2B-selective compounds have been discovered, each with remarkably unique structural motifs. ...Small molecule therap …
Allosteric inhibitors of GluN2B-containing receptors are among the most potential NMDAR targeting drugs. Since the discovery of ifenprodi …
N-{2-[4-(4-[125I]Iodobenzyl)-piperidin-1-ylmethyl]benzoimidazol-5-yl}-methanesulfonamide.
Chopra A. Chopra A. 2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2011 Jan 31 [updated 2011 Mar 31]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21473036 Free Books & Documents. Review.
These receptors are involved in the development of neurological conditions such as Parkinson's disease, Alzheimer's disease, bipolar disorder, etc (2, 3). The structure, distribution, and function of the NMDAR in the rodent brain has been reviewed else …
These receptors are involved in the development of neurological conditions such as Parkinson's disease, Alzheimer's …
Modulation of learning and memory by natural polyamines.
Guerra GP, Rubin MA, Mello CF. Guerra GP, et al. Pharmacol Res. 2016 Oct;112:99-118. doi: 10.1016/j.phrs.2016.03.023. Epub 2016 Mar 22. Pharmacol Res. 2016. PMID: 27015893 Free article. Review.
The interaction with the opioid system, the facilitation and disruption of morphine-induced reward and the effect of polyamines and putative polyamine antagonists on animal models of cognitive diseases, such as Alzheimer's, Huntington, acute neuroinflammation and br …
The interaction with the opioid system, the facilitation and disruption of morphine-induced reward and the effect of polyamines and putative …
Direct administration of ifenprodil and citalopram into the nucleus accumbens inhibits cue-induced nicotine seeking and associated glutamatergic plasticity.
Leyrer-Jackson JM, Piña JA, McCallum J, Foster Olive M, Gipson CD. Leyrer-Jackson JM, et al. Brain Struct Funct. 2020 Sep;225(7):1967-1978. doi: 10.1007/s00429-020-02103-9. Epub 2020 Jun 26. Brain Struct Funct. 2020. PMID: 32591928 Free PMC article.
Prior to reinstatement, rats received intra-NAcore injections of either ifenprodil, citalopram or artificial cerebral spinal fluid (15 min prior), or GluN2B or control siRNAs (3 consecutive days prior). ...Together, these results indicate that the therapeutic effects of …
Prior to reinstatement, rats received intra-NAcore injections of either ifenprodil, citalopram or artificial cerebral spinal fluid (1 …
Development and Validation of [3H]OF-NB1 for Preclinical Assessment of GluN1/2B Candidate Drugs.
Ahmed H, Gisler L, Elghazawy NH, Keller C, Sippl W, Liang SH, Haider A, Ametamey SM. Ahmed H, et al. Pharmaceuticals (Basel). 2022 Aug 2;15(8):960. doi: 10.3390/ph15080960. Pharmaceuticals (Basel). 2022. PMID: 36015108 Free PMC article.
GluN2B-enriched N-methyl-D-aspartate receptors (NMDARs) are implicated in several neurodegenerative and psychiatric diseases, such as Alzheimer's disease. No clinically valid GluN1/2B therapeutic exists due to a lack of selective GluN2B imaging tools, and the …
GluN2B-enriched N-methyl-D-aspartate receptors (NMDARs) are implicated in several neurodegenerative and psychiatric diseases, such as Alz …
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
Gogas KR. Gogas KR. Curr Opin Pharmacol. 2006 Feb;6(1):68-74. doi: 10.1016/j.coph.2005.11.001. Epub 2005 Dec 22. Curr Opin Pharmacol. 2006. PMID: 16376149 Review.
Over the past decade, there have been major advances in our understanding of the role of glutamate and N-methyl-d-aspartate (NMDA) receptors in several disorders of the central nervous system, including stroke, Parkinson's disease, Huntington's disease and chronic/n …
Over the past decade, there have been major advances in our understanding of the role of glutamate and N-methyl-d-aspartate (NMDA) receptors …
52 results